ERBB2 and breast cancer: In HER2+ breast cancer, the recent results of the KEYNOTE-014/PANACEA trial showed that 15% of the patients who had PD-L1+ tumors had partial responses to combined anti-PD-1 mAb (pembrolizumab) with trastuzumab without radiation [4].